IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment
Total serum IgG level is a surrogate marker of hepatitis C (HC) severity. Antibodies (Abs) to microbial glycans could be markers of HC severity caused by the translocation of microbial products. The level of anti-glycan (AG) Abs was analysed in serum samples of patients (n=128) with chronic HC in EL...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2018/4639805 |
id |
doaj-f8eb40675e444082b5dda88d45d38a20 |
---|---|
record_format |
Article |
spelling |
doaj-f8eb40675e444082b5dda88d45d38a202020-11-24T22:52:31ZengHindawi LimitedDisease Markers0278-02401875-86302018-01-01201810.1155/2018/46398054639805IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral TreatmentEugeniy Smorodin0Boris Sergeyev1Oleg Kurtenkov2Tatiana Kuznetsova3Julia Geller4Department of Oncology & Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, EstoniaDepartment of Oncology & Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, EstoniaDepartment of Oncology & Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, EstoniaDepartment of Virology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, EstoniaDepartment of Virology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, EstoniaTotal serum IgG level is a surrogate marker of hepatitis C (HC) severity. Antibodies (Abs) to microbial glycans could be markers of HC severity caused by the translocation of microbial products. The level of anti-glycan (AG) Abs was analysed in serum samples of patients (n=128) with chronic HC in ELISA using fourteen synthetic glycans present in microbes and adhesins to evaluate the association of Abs with clinical parameters and the efficacy of antiviral treatment. The anti-GlcNAcβ IgG level was significantly higher in patients with fibrosis (P=0.021) and severe portal inflammation (P<0.001) regardless of other clinical parameters. The ROC curve analysis showed sensitivity of 0.59, specificity of 0.84, and AUC of 0.71 in discriminating F0 from F1–4 (HCV genotype-1b-infected patients). The level of anti-GA2 Abs before Peg-IFN/RBV treatment was significantly higher in nonsustained viral response (non-SVR) to treatment than in SVR (P=0.033). ROC analysis showed sensitivity of 0.62, specificity of 0.70, and AUC of 64. Correlations of AG Abs to clinical parameters were found. The quantification of anti-GlcNAcβ Abs deserves attention in assessment of the hepatic damage while anti-GA2 Abs may be a sign of immune response related to the antiviral treatment.http://dx.doi.org/10.1155/2018/4639805 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eugeniy Smorodin Boris Sergeyev Oleg Kurtenkov Tatiana Kuznetsova Julia Geller |
spellingShingle |
Eugeniy Smorodin Boris Sergeyev Oleg Kurtenkov Tatiana Kuznetsova Julia Geller IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment Disease Markers |
author_facet |
Eugeniy Smorodin Boris Sergeyev Oleg Kurtenkov Tatiana Kuznetsova Julia Geller |
author_sort |
Eugeniy Smorodin |
title |
IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment |
title_short |
IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment |
title_full |
IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment |
title_fullStr |
IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment |
title_full_unstemmed |
IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment |
title_sort |
igg antibodies to glcnacβ and asialo-gm2 (ga2) glycans as potential markers of liver damage in chronic hepatitis c and the efficacy of antiviral treatment |
publisher |
Hindawi Limited |
series |
Disease Markers |
issn |
0278-0240 1875-8630 |
publishDate |
2018-01-01 |
description |
Total serum IgG level is a surrogate marker of hepatitis C (HC) severity. Antibodies (Abs) to microbial glycans could be markers of HC severity caused by the translocation of microbial products. The level of anti-glycan (AG) Abs was analysed in serum samples of patients (n=128) with chronic HC in ELISA using fourteen synthetic glycans present in microbes and adhesins to evaluate the association of Abs with clinical parameters and the efficacy of antiviral treatment. The anti-GlcNAcβ IgG level was significantly higher in patients with fibrosis (P=0.021) and severe portal inflammation (P<0.001) regardless of other clinical parameters. The ROC curve analysis showed sensitivity of 0.59, specificity of 0.84, and AUC of 0.71 in discriminating F0 from F1–4 (HCV genotype-1b-infected patients). The level of anti-GA2 Abs before Peg-IFN/RBV treatment was significantly higher in nonsustained viral response (non-SVR) to treatment than in SVR (P=0.033). ROC analysis showed sensitivity of 0.62, specificity of 0.70, and AUC of 64. Correlations of AG Abs to clinical parameters were found. The quantification of anti-GlcNAcβ Abs deserves attention in assessment of the hepatic damage while anti-GA2 Abs may be a sign of immune response related to the antiviral treatment. |
url |
http://dx.doi.org/10.1155/2018/4639805 |
work_keys_str_mv |
AT eugeniysmorodin iggantibodiestoglcnacbandasialogm2ga2glycansaspotentialmarkersofliverdamageinchronichepatitiscandtheefficacyofantiviraltreatment AT borissergeyev iggantibodiestoglcnacbandasialogm2ga2glycansaspotentialmarkersofliverdamageinchronichepatitiscandtheefficacyofantiviraltreatment AT olegkurtenkov iggantibodiestoglcnacbandasialogm2ga2glycansaspotentialmarkersofliverdamageinchronichepatitiscandtheefficacyofantiviraltreatment AT tatianakuznetsova iggantibodiestoglcnacbandasialogm2ga2glycansaspotentialmarkersofliverdamageinchronichepatitiscandtheefficacyofantiviraltreatment AT juliageller iggantibodiestoglcnacbandasialogm2ga2glycansaspotentialmarkersofliverdamageinchronichepatitiscandtheefficacyofantiviraltreatment |
_version_ |
1725665654677176320 |